exRNAdisease

Entry Detail

---



General Information

Database ID: exR0083620 RNA Name: TRIO RNA Type: mRNA Chromosome: chr5 Starnd: + Coordinate: Start Site(bp): 14143342 End Site(bp): 14532128 External Links: ENSG00000038382

Disease Information

Disease Name: Fragile X Syndrome Disease Category: Congenital, Hereditary, and Neonatal Diseases and Abnormalities MeSH ID: D005600 Type: Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities Alias: Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID: GSE83556 Description: Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions Experimental Design: Disease vs Control Case Disease Type: Fragile X Syndrome Case Disease SubType: NA Case Sample: Fragile X Syndrome Control Sample: Normal Number of Case: 22 Number of Control: 18 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AAK1 chr2 69457997 69674349 - AC245033.1 chr15 82536788 82573194 - ACTG1 chr17 81509971 81523847 - ACTN1 chr14 68874143 68979440 - ACTN4 chr19 38647649 38731589 + ADAMTS1 chr21 26835755 26845409 - ADCY1 chr7 45574140 45723116 + ADK chr10 74151202 74709963 + AKR7A2 chr1 19303965 19312146 - AKT2 chr19 40230317 40285536 - AL138752.2 chr9 37588413 38068687 - miRNA targets: miRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa-miR-140-5p chr16 69933103 69933124 + hsa-miR-34c-5p chr11 111513451 111513473 + hsa-miR-490-3p chr7 136903242 136903263 + hsa-miR-423-5p chr17 30117095 30117117 + hsa-miR-873-5p chr9 28888925 28888945 - hsa-miR-1286 chr22 20249145 20249165 - circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC010442.1 chr5 466124 473098 - AC114980.1 chr5 93860669 93863825 - AC144548.1 chr12 110387463 110445548 - AC245033.4 chr15 82533175 82540008 - AD000090.1 chr19 35557956 35581954 + Display:

Experiment Detail

GEO ID: GSE83556 Sample Source: Amniotic Fluid Source Fraction: Supernatant Platform: GPL570 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 17063 Sample treatment protocol: RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min). RNA Extract protocol: All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water. RNA library preparation protocol: RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference

PMID: NA Title: NA Author: NA Journal: NA Description: NA